Skip to main content
Clinical Trials/NCT02388880
NCT02388880
Terminated
Not Applicable

Physiological Effects of Intrathoracic Pressure Regulation in Patients With Decreased Cerebral Perfusion Due to Brain Injury or Intracranial Pathology (4 Hour Use)

Advanced Circulatory Systems1 site in 1 country3 target enrollmentFebruary 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head Injury
Sponsor
Advanced Circulatory Systems
Enrollment
3
Locations
1
Primary Endpoint
Cerebral Perfusion Pressure (CPP)
Status
Terminated
Last Updated
7 years ago

Overview

Brief Summary

The purpose of the study is to evaluate the physiological response to application of the Intrathoracic Pressure Regulator (ITPR) in patients with compromised cerebral circulation. The study will evaluate the physiological response to intrathoracic pressure regulation (IPR) therapy in hemodynamically stable patients with compromised cerebral circulation who are on ventilatory support.

Registry
clinicaltrials.gov
Start Date
February 2015
End Date
November 2016
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Advanced Circulatory Systems
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥18 years of age
  • intubated and mechanically ventilated on a volume controlled mode
  • head injury or other intracranial pathology and compromised cerebral perfusion
  • arterial line in place or alternative with continuous pressure monitoring
  • SpO2 ≥90%
  • mean arterial pressure \>55
  • admission to ICU or about to undergo neurosurgery with planned placement of an invasive intracranial pressure monitor
  • inclusion presents no significant delays to planned emergent neurosurgery
  • prior written informed consent

Exclusion Criteria

  • cardiac or pulmonary injury
  • confirmed pneumothorax or hemothorax
  • serious neck injury resulting in neck swelling with jugular venous compression
  • evidence of ongoing uncontrolled bleeding
  • respiratory disease such as COPD, interstitial lung disease, or other parenchymal or pulmonary vascular disease
  • marked hypertension at time of device use defined as systolic blood pressure \>180 mmHg
  • congestive heart failure
  • women with positive serum or urine pregnancy test or breast feeding

Outcomes

Primary Outcomes

Cerebral Perfusion Pressure (CPP)

Time Frame: During 240 minutes of device use

Change from baseline CPP compared with the CPP during use of the ITPR.

Secondary Outcomes

  • Mean Arterial Pressure (MAP)(baseline to end of ITPR use)
  • End-tidal Carbon Dioxide (EtCO2)(baseline to end of ITPR use)
  • Intracranial Pressure (ICP)(baseline to end of ITPR use)

Study Sites (1)

Loading locations...

Similar Trials